HER2 Is Not a Predictive Biomarker of Benefit From Up-front Chemotherapy Plus Bevacizumab or Anti-EGFR, but Negative Prognostic Factor in pMMR/MSS RAS/BRAF Wild-Type mCRC By Ogkologos - September 29, 2025 194 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a large analysis of HER2 status in patients enrolled in 8 randomised clinical trials Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR “My Heart Will Always Hurt”: How I Honor My Childhood Best... April 26, 2022 Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD... July 19, 2022 FDA Approves Amivantamab-vmjw for EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung... March 8, 2024 Addressing Disparities and Raising Awareness During National Black Family Cancer Awareness... June 15, 2023 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Nivolumab / Relatlimab EMA Recommends Extension of Therapeutic Indications for Lisocabtagene Maraleucel Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in... How Your Primary Care Provider Can Help You Throughout Your Cancer...
